tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat. tiakis and Stanford University are now preparing for a Phase II in Pulmonary Arterial Hypertension (PAH). tiakis´management will be attending the upcoming JP Morgan Healthcare conference in San Francisco. https://lnkd.in/deHNestP #pulmonarydiseases #cardiovasculardiseases #pulmonaryarterialhypertension #clinicaltrial #FDA #Phase2 #Tiprelestat #StanfordUniversity
tiakis Biotech AG
Biotechnologieforschung
Kiel, Schleswig-Holstein 284 Follower:innen
Next generation preventive therapeutic biotech company based on clinical stage pioneering tissue protective drug
Info
tiakis biotech AG, formerly Proteo Biotech AG, located in the north of Germany, is the next generation preventive therapeutic technology company based on its clinical stage pioneering tissue protective drug 'Tiprelestat', which is identical to a human recombinant anti-inflammatory protein. The company is fully dedicated to its novel therapy approach to treat life-threatening unmet medical need diseases. Our approach represents a paradigm shift towards a preventive approach by e.g. protecting against inflammatory organ damage and failure following invasive major surgery, by offering the potential for reversing the vascular pathology of pulmonary arterial hypertension or by prevention of serious disease progression of COVID-19.
- Website
-
https://www.tiakis.bio
Externer Link zu tiakis Biotech AG
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Kiel, Schleswig-Holstein
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2000
- Spezialgebiete
- tissue protective drug, game changing innovation, PAH, Elafin, COMCOVID CLINICAL TRIAL, TIPRELESTAT und human protein elafin
Orte
-
Primär
Wegbeschreibung
Sophienblatt
40
Kiel, Schleswig-Holstein 23104, DE